Frontiers in Cell and Developmental Biology (Feb 2021)
RETRACTED: Exosomal miR-128-3p Promotes Epithelial-to-Mesenchymal Transition in Colorectal Cancer Cells by Targeting FOXO4 via TGF-β/SMAD and JAK/STAT3 Signaling
- Jian Bai,
- Jian Bai,
- Jian Bai,
- Jian Bai,
- Xue Zhang,
- Xue Zhang,
- Xue Zhang,
- Xue Zhang,
- Dongdong Shi,
- Dongdong Shi,
- Dongdong Shi,
- Zhenxian Xiang,
- Zhenxian Xiang,
- Zhenxian Xiang,
- Shuyi Wang,
- Shuyi Wang,
- Shuyi Wang,
- Chaogang Yang,
- Chaogang Yang,
- Chaogang Yang,
- Qing Liu,
- Qing Liu,
- Qing Liu,
- Sihao Huang,
- Sihao Huang,
- Sihao Huang,
- Yan Fang,
- Yan Fang,
- Yan Fang,
- Weisong Zhang,
- Weisong Zhang,
- Weisong Zhang,
- Jialin Song,
- Jialin Song,
- Jialin Song,
- Bin Xiong,
- Bin Xiong,
- Bin Xiong
Affiliations
- Jian Bai
- Department of Gastrointestinal Surgery & Department of Gastric and Colorectal Surgical Oncology, Zhongnan Hospital of Wuhan University, Wuhan, China
- Jian Bai
- Department of Anesthesiology, Peking University Third Hospital, Beijing, China
- Jian Bai
- Hubei Key Laboratory of Tumor Biological Behaviors, Wuhan, China
- Jian Bai
- Hubei Cancer Clinical Study Center, Wuhan, China
- Xue Zhang
- Hubei Key Laboratory of Tumor Biological Behaviors, Wuhan, China
- Xue Zhang
- Hubei Cancer Clinical Study Center, Wuhan, China
- Xue Zhang
- Department of General Practice, Beijing Friendship Hospital, Capital Medical University, Beijing, China
- Xue Zhang
- Department of Radiation Oncology and Medical Oncology, Zhongnan Hospital of Wuhan University, Wuhan, China
- Dongdong Shi
- Department of Gastrointestinal Surgery & Department of Gastric and Colorectal Surgical Oncology, Zhongnan Hospital of Wuhan University, Wuhan, China
- Dongdong Shi
- Hubei Key Laboratory of Tumor Biological Behaviors, Wuhan, China
- Dongdong Shi
- Hubei Cancer Clinical Study Center, Wuhan, China
- Zhenxian Xiang
- Department of Gastrointestinal Surgery & Department of Gastric and Colorectal Surgical Oncology, Zhongnan Hospital of Wuhan University, Wuhan, China
- Zhenxian Xiang
- Hubei Key Laboratory of Tumor Biological Behaviors, Wuhan, China
- Zhenxian Xiang
- Hubei Cancer Clinical Study Center, Wuhan, China
- Shuyi Wang
- Department of Gastrointestinal Surgery & Department of Gastric and Colorectal Surgical Oncology, Zhongnan Hospital of Wuhan University, Wuhan, China
- Shuyi Wang
- Hubei Key Laboratory of Tumor Biological Behaviors, Wuhan, China
- Shuyi Wang
- Hubei Cancer Clinical Study Center, Wuhan, China
- Chaogang Yang
- Department of Gastrointestinal Surgery & Department of Gastric and Colorectal Surgical Oncology, Zhongnan Hospital of Wuhan University, Wuhan, China
- Chaogang Yang
- Hubei Key Laboratory of Tumor Biological Behaviors, Wuhan, China
- Chaogang Yang
- Hubei Cancer Clinical Study Center, Wuhan, China
- Qing Liu
- Department of Gastrointestinal Surgery & Department of Gastric and Colorectal Surgical Oncology, Zhongnan Hospital of Wuhan University, Wuhan, China
- Qing Liu
- Hubei Key Laboratory of Tumor Biological Behaviors, Wuhan, China
- Qing Liu
- Hubei Cancer Clinical Study Center, Wuhan, China
- Sihao Huang
- Department of Gastrointestinal Surgery & Department of Gastric and Colorectal Surgical Oncology, Zhongnan Hospital of Wuhan University, Wuhan, China
- Sihao Huang
- Hubei Key Laboratory of Tumor Biological Behaviors, Wuhan, China
- Sihao Huang
- Hubei Cancer Clinical Study Center, Wuhan, China
- Yan Fang
- Department of Gastrointestinal Surgery & Department of Gastric and Colorectal Surgical Oncology, Zhongnan Hospital of Wuhan University, Wuhan, China
- Yan Fang
- Hubei Key Laboratory of Tumor Biological Behaviors, Wuhan, China
- Yan Fang
- Hubei Cancer Clinical Study Center, Wuhan, China
- Weisong Zhang
- Department of Gastrointestinal Surgery & Department of Gastric and Colorectal Surgical Oncology, Zhongnan Hospital of Wuhan University, Wuhan, China
- Weisong Zhang
- Hubei Key Laboratory of Tumor Biological Behaviors, Wuhan, China
- Weisong Zhang
- Hubei Cancer Clinical Study Center, Wuhan, China
- Jialin Song
- Department of Gastrointestinal Surgery & Department of Gastric and Colorectal Surgical Oncology, Zhongnan Hospital of Wuhan University, Wuhan, China
- Jialin Song
- Hubei Key Laboratory of Tumor Biological Behaviors, Wuhan, China
- Jialin Song
- Hubei Cancer Clinical Study Center, Wuhan, China
- Bin Xiong
- Department of Gastrointestinal Surgery & Department of Gastric and Colorectal Surgical Oncology, Zhongnan Hospital of Wuhan University, Wuhan, China
- Bin Xiong
- Hubei Key Laboratory of Tumor Biological Behaviors, Wuhan, China
- Bin Xiong
- Hubei Cancer Clinical Study Center, Wuhan, China
- DOI
- https://doi.org/10.3389/fcell.2021.568738
- Journal volume & issue
-
Vol. 9
Abstract
Epithelial-to-mesenchymal transition (EMT) is a key process that occurs during tumor metastasis, affecting a variety of malignancies including colorectal cancer (CRC). Exosomes mediate cell-cell communication by transporting cell-derived proteins and nucleic acids, including microRNAs (miRNAs). Exosomal delivery of miRNAs plays an important role in tumor initiation, development, and progression. In this study, we investigated the effect of exosomal transfer between CRC cells and aimed to identify specific miRNAs and downstream targets involved in EMT and metastasis in CRC cells. High expression of miR-128-3p was identified in exosomes derived from EMT-induced HCT-116 cells. Altered miR-128-3p expression in CRC cells led to distinct changes in proliferation, migration, invasion, and EMT. Mechanistically, miR-128-3p overexpression downregulated the expression of FOXO4 and induced the activation of TGF-β/SMAD and JAK/STAT3 signaling in CRC cells and xenografted tumors, which led to EMT. Clinically, high expression of miR-128-3p was significantly associated with perineural invasion, lymphovascular invasion, tumor stage, and CA 19-9 content in CRC patients. We revealed that exosomal miR-128-3p regulates EMT by directly suppressing its downstream target gene FOXO4 to activate TGF-β/SMAD and JAK/STAT3 signaling, and the properties of the miR-128-3p/FOXO4 axis were horizontally transferred via exosomal delivery. In turn, exosomal miR-128-3p could be considered as a new therapeutic vehicle for CRC.
Keywords